A comparison of endovascular repair to medical management for acute vs subacute uncomplicated type B aortic dissections: Presented at the Thirty-sixth Annual Meeting of the Eastern Vascular Society, Philadelphia, Pennsylvania, September 29-October 1, 2022.

Our results found lower 3-year survival in the acute TEVAR group compared with the medical management group. There was no 3-year survival benefit found in patients with UTBAD who underwent subacute TEVAR compared with medical management. This suggests the need for further studies looking at the necessity for TEVAR when compared with medical management for UTBAD as it is non-inferior to medical management. Higher rates of 3-year survival and lower rates of 3-year rupture in the subacute TEVAR group compared with the acute TEVAR group suggest superiority of subacute TEVAR. Further investigations are needed to determine the long-term benefit and optimal timing of TEVAR for acute UTBAD.